Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

Summary

This is a Phase 1/2 open-label study to evaluate the safety, tolerability, steady-state pharmacokinetic (PK) and pharmacodynamics (PD) of a lysine-specific demethylase 1 (LSD1) inhibitor, bomedemstat (IMG-7289/MK-3543), administered orally once daily in participants with myelofibrosis. The primary hypothesis is that bomedemstat is a safe and tolerable orally available agent when administered to participants with myelofibrosis including primary myelofibrosis (PMF), post-polycythaemia vera-myelofibrosis (PPVMF), and post-essential thrombocythaemia-myelofibrosis (PET-MF) (collectively referred to as 'MF'); inhibition of LSD1 by bomedemstat will reduce spleen size in those with splenomegaly, improve haematopoiesis and reduce constitutional symptoms associated with these disorders.

Timeline

Start

2017-07-18

Primary completion

2022-03-08

Completion

2022-03-08

Publications

• Gill H, Yacoub A, Gerds AT, Shortt J, Rossetti JM, Mead AJ, Gothert JR, Koschmieder S, Ewing J, Halpern AB, Palandri F, Passamonti F, Mesa R, Marchetti M, Harrison C, Vannucchi AM, Watts JM, Wood JC, Ross DM, Peppe J, Natsoulis G, Rienhoff HY Jr. The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study. Blood Adv. 2026 Jul 14;10(13):4585-4594. doi: 10.1182/bloodadvances.2025018141.

Drugs

Indications